
U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.



NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION		PAGE 2 OF 3 PAGES
MATERIALS LICENSE SUPPLEMENTARY SHEET	License No.: 53-17797-01	Docket or Reference No.: 030-13337	
	Amendment No. 44	030-13337	

CONDITIONS

- 10. Licensed material may be used or stored at the licensee's facilities located at: 347 North Kuakini Street, Honolulu (Island of Oahu), Hawaii, 96817
- 11. The Radiation Safety Officer (RSO) for this license is Harry F. Palmer, M.C.E.
- 12. Licensed material shall only be used by, or under the supervision of:
 - A. Individuals permitted to work as authorized users, and/or authorized nuclear pharmacists in accordance with 10 CFR 35.13 and 10 CFR 35.14.
 - B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized Users	Material and Use
Michael Chervonski, M.D.	35.100; 35.200; 35.300 limited to the oral administration of sodium iodide I-131
Andy K. Chon, M.D.	35.100; 35.200; 35.300 limited to the oral administration of sodium iodide I-131
Mitchell T. Gudmundsson, M.D.	35.100; 35.200; 35.300 limited to the oral administration of sodium iodide I-131
Mykol Larvie, M.D.	35.100; 35.200; 35.300
Michael C.C. Ling, M.D.	35.100; 35.200; 35.300
Zachary B. Love, M.D.	35.100; 35.200; 35.300 limited to the oral administration of sodium iodide I-131
Rajiv Girish Rao, M.D.	35.100; 35.200; 35.300 limited to the oral administration of sodium iodide I-131
Charles N. Weber, M.D.	35.100; 35.200; 35.300 limited to the oral administration of sodium iodide I-131
Lisa L. Wong, M.D.	35.100; 35.200

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION PAGE 3 OF 3 PAGES			
MATERIALS LICENSE	License No.: 53-17797-01	Docket or Reference No.: 030-13337		
SUPPLEMENTARY SHEET	Amendment No. 44			
13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations. A. Application dated March 12, 2024 (ML24072A574) B. Letter dated July 1, 2024 (ML24221A056) C. Letter dated July 24, 2024 (ML24221A059) D. Letter dated August 19, 2024 (ML24241A140) E. Letter dated August 39, 2024 (ML24247A259) F. Letter dated October 25, 2024 (ML24302A241)				
	FOR	R THE U.S. NUCLEAR REGULATORY COMMISSION		
Date: January 14, 2025		Samantha Everett Region 4		